Inovio Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jacqueline E. Shea
- Full Time Employees
- 112
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 660 West Germantown Pike Plymouth Meeting PA United States of America 19462
- IPO Date
- Dec 8, 1998
- CIK
- 0001055726
- Website
- inovio.com
- Similar Companies
- Business
- Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines designed to treat and protect against HPV-related diseases, cancer, and infectious diseases. Its core products include DNA plasmid-based medicines and proprietary CELLECTRA® delivery devices which facilitate intracellular delivery of these DNA medicines without chemical adjuvants or viral vectors. The company’s pipeline features candidates such as INO-3107 for recurrent respiratory papillomatosis (RRP), ongoing development of DNA medicines targeting HPV-related anal dysplasia, oropharyngeal squamous cell carcinoma (OPSCC), glioblastoma multiforme (GBM), and vaccine boosters for Ebola. Inovio operates primarily in North America, Europe, and Asia through collaborations. Founded in 1979 and headquartered in Plymouth Meeting, Pennsylvania, Inovio maintains strategic partnerships including a clinical collaboration and supply agreement with Coherus BioSciences for combination therapy trials and collaboration with ApolloBio for Phase 3 trials in China. In the last 1-2 years, Inovio has focused on advancing INO-3107 through the regulatory pathway, initiating device design verification testing of its CELLECTRA device to support a Biologics License Application (BLA) submission planned for late 2025, aiming for FDA acceptance by year-end and potential approval by mid-2026. The company has reported positive Phase 1/2 trial results demonstrating significant clinical benefit in reducing surgical interventions for RRP patients. Additionally, Inovio advanced proof-of-concept trials for DNA-encoded monoclonal antibodies as a next-generation platform. The company strengthened its financial position with over $60 million in net proceeds from equity offerings in 2024 and completed a $25 million public offering in mid-2025. These capital raises support ongoing clinical development and commercial readiness, including launch planning for INO-3107 and expansion of its DNA medicines platform technologies in immuno-oncology and infectious diseases. Inovio continues to pursue innovation via acquisitions such as Bioject Medical Technologies' needle-free injection assets to enhance its delivery technology portfolio. Overall, Inovio is focused on leveraging its proprietary DNA medicine technology and delivery systems to develop a novel class of therapeutics for viral infections, HPV-associated malignancies, and cancer, positioning itself for transition to a commercial-stage biotechnology company within the near future.
Company News
Bet on 5 Top-Ranked Stocks With Rising P/E
INOVIO to Participate in Upcoming Investor Conferences
Inovio Pharmaceuticals Q2 Earnings Call Highlights
Inovio Pharmaceuticals, Inc. (INO) Q2 2026 Earnings Call Transcript
INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Bet on 5 Top-Ranked Stocks With Rising P/E
INOVIO to Report Second Quarter Financial Results on August 12, 2026
INOVIO Announces Pricing of $20.0 Million Public Offering
INOVIO Announces Pricing of $20.0 Million Public Offering
INOVIO Announces Proposed Public Offering
Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm
Inovio Pharmaceuticals, Inc. (INO) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm
INOVIO to Participate in Upcoming Scientific and Investor Conferences
Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances
Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China
Inovio: All Eyes On INO-3107 As Binary FDA Decision Looms
Inovio Pharmaceuticals, Inc. (INO) Q1 2026 Earnings Call Transcript
INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights